Stay updated with breaking news from Final Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership – – New Data Highlight Magrolimab’s Potential to Alter the Tumor... | June 1, 2023
BeiGene's BTKi is approved in more than 65 markets globally BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a
BeiGene’s BTKi is approved in more than 65 markets globally ... | May 30, 2023
Sam Durrance, who as an astronomer was one of the first non-career astronauts to fly after the loss of space shuttle Challenger, has died at the age of 79.